^{109TH CONGRESS} 2D SESSION H.R.6147

To establish an Advisory Committee on Gestational Diabetes, to provide grants to better understand and reduce gestational diabetes, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

September 21, 2006

Mr. FOSSELLA (for himself and Mr. ENGEL) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

- To establish an Advisory Committee on Gestational Diabetes, to provide grants to better understand and reduce gestational diabetes, and for other purposes.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

- 4 This Act may be cited as the "Gestational Diabetes
- 5 Act of 2006" or the "GEDI Act".
- 6 SEC. 2. FINDINGS.
- 7 Congress finds the following:

(1) The prevalence of gestational diabetes
 among pregnant women in the United States is in creasing.

4 (2) Gestational diabetes, which is similar to
5 chronic forms of diabetes, normally appears at 24 to
6 28 weeks' gestation and occurs in approximately 4
7 to 8 percent of pregnant women.

8 (3) The causes of gestational diabetes are un9 known, but genetics, excess weight, ethnicity, and
10 age are considered risk factors for the condition.

(4) There is disagreement among physicians
about how to treat gestational diabetes, as well as
the effectiveness of current treatment regimens.

14 (5) Gestational diabetes, which can cause
15 preeclampsia, also increases a pregnant woman's
16 risk for developing the condition in subsequent preg17 nancies.

(6) Infants of women who develop gestational
diabetes may have extreme increases in birth weight
and the risks related to difficulties during the birthing process, and some of the infants born to these
women—

23 (A) may subsequently have low blood sugar
24 or jaundice during the newborn period;

 $\mathbf{2}$

| 1 | (B) are at an increased risk for obesity |
|----|--|
| 2 | and birth trauma; and |
| 3 | (C) are at an increased risk of developing |
| 4 | type 2 diabetes as an adolescent or adult. |
| 5 | (7) About 15 percent of infertility cases are |
| 6 | linked to weight disorders, most often being over- |
| 7 | weight or obese. Obesity affects fertility and is also |
| 8 | associated with increased morbidity for both the |
| 9 | mother and the child. |
| 10 | (8) Improved nutritional and physical health |
| 11 | care, both before and during pregnancy, may signifi- |
| 12 | cantly decrease the rates of gestational diabetes. |
| 13 | (9) Ten percent of obese pregnant women are |
| 14 | estimated to have gestational diabetes. |
| 15 | (10) Obesity potentially leads to a higher rate |
| 16 | of induction and primary caesarean section. |
| 17 | SEC. 3. GESTATIONAL DIABETES. |
| 18 | The Public Health Service Act (42 U.S.C. 201 et |
| 19 | seq.) is amended by adding at the end the following: |

3

"TITLE XXIX—GESTATIONAL DIABETES

1

2

4

3 "SEC. 2901. UNDERSTANDING AND MONITORING GESTA4 TIONAL DIABETES AND OBESITY DURING
5 PREGNANCY.

6 "(a) IN GENERAL.—The Secretary of Health and
7 Human Services, acting through the Director of the Cen8 ters for Disease Control and Prevention, shall convene a
9 Research Advisory Committee.

10 "(b) MEMBERSHIP.—Membership in the Research
11 Advisory Committee—

12 "(1) shall include— "(A) a representative from the Agency for 13 14 Healthcare Research and Quality; "(B) a representative from the Centers for 15 16 Disease Control and Prevention; "(C) a representative from the National 17 18 Institutes of Health; "(D) a representative from the Office of 19 20 Minority Health; "(E) a representative from the Indian 21 Health Service; and 22

23 "(F) representatives from other appro24 priate Federal agencies; and

•HR 6147 IH

"(2) may include representatives from other ap propriate organizations.

3 "(c) MATTERS TO BE STUDIED.—The Director of 4 the Centers for Disease Control and Prevention, in consultation with the Research Advisory Committee, shall de-5 velop a multisite, gestational diabetes research project 6 7 within the diabetes program of the Centers for Disease 8 Control and Prevention to expand and enhance surveillance data and public health research on gestational diabe-9 10 tes. The project shall address—

11 "(1) the use of consistent standards to measure12 gestational diabetes;

"(2) the procedures to establish accurate and
efficient systems for the collection of gestational diabetes data within each State;

"(3) the progress of collaborative activities with
the National Vital Statistics System, the National
Center for Health Statistics, and State health departments with respect to the standard birth certificate, in order to improve surveillance of gestational
diabetes;

"(4) the establishment of procedures for reporting gestational diabetes data to the Centers for Disease Control and Prevention;

 $\mathbf{5}$

"(5) post-natal methods of tracking women who 1 2 had gestational diabetes after delivery and the devel-3 opment of ways to lower the incidence of type 2 dia-4 betes in that population; "(6) variations in the distribution of diagnosed 5 6 and undiagnosed diabetes and of impaired fasting 7 glucose tolerance and impaired fasting glucose with-8 in and among groups of women; and 9 "(7) factors that influence risks for gestational 10 diabetes and obesity during pregnancy and complica-11 tions during childbirth among women, including cul-12 tural, racial, ethnic, geographic, demographic, socio-13 economic, and genetic factors. 14 "(d) MEETINGS.—Not later than 1 year after the es-15 tablishment of the gestational diabetes research project under subsection (c), and annually thereafter, the Re-16 17 search Advisory Committee shall meet to assess the 18 progress of the project and to update the Secretary of 19 Health and Human Services, if necessary. 20 "(e) REPORT.—Not later than 2 years after the date 21 of enactment of the Gestational Diabetes Act of 2006, and 22 annually thereafter, the Director of the Centers for Dis-23 ease Control and Prevention shall generate a report on

24 the prevalence of gestational diabetes and disseminate the

report to the Secretary of Health and Human Services and
 appropriate Federal and non-Federal agencies.

3 "SEC. 2902. DEMONSTRATION GRANTS TO LOWER THE RATE 4 OF GESTATIONAL DIABETES AND OBESITY 5 DURING PREGNANCY.

6 "(a) IN GENERAL.—The Secretary of Health and 7 Human Services, acting through the Director of the Cen-8 ters for Disease Control and Prevention, in consultation 9 with the Research Advisory Committee established under 10 section 2901, shall award grants, on a competitive basis, to eligible entities for demonstration projects that test 11 12 specified hypotheses about interventions designed to reduce the incidence of gestational diabetes and obesity 13 among young women and implement relevant activities. In 14 15 making such grants, the Director shall act on scientific findings that— 16

17 "(1) the prevention or delay of type 2 diabetes18 is possible for older adults;

"(2) the diabetes risk status of an individual is
likely established during the individual's earlier age
(adolescence through the age of 30);

"(3) women are uniquely capable of demonstrating their diabetes risk status, through acquiring gestational diabetes during the challenge of pregnancy;

| 1 | "(4) gestational diabetes itself is a well-estab- |
|----------|---|
| 2 | lished risk factor for a woman's subsequent transi- |
| 3 | tion to type 2 diabetes; and |
| 4 | "(5) gestational diabetes may confer risks of fu- |
| 5 | ture obesity and type 2 diabetes on the children of |
| 6 | a mother with gestational diabetes. |
| 7 | "(b) APPLICATION.—An eligible entity desiring to re- |
| 8 | ceive a grant under this section shall submit to the Direc- |
| 9 | tor of the Centers for Disease Control and Prevention— |
| 10 | ((1) an application at such time, in such man- |
| 11 | ner, and containing such information as the Director |
| 12 | may require; and |
| 13 | "(2) a plan to— |
| 14 | "(A) lower the rate of gestational diabetes |
| 15 | and obesity during pregnancy; or |
| 16 | "(B) conduct post-natal methods of track- |
| 17 | ing women who had gestational diabetes in |
| 18 | order to develop ways to lower the incidence of |
| 19 | such mothers developing type 2 diabetes. |
| 20 | "(c) USES OF FUNDS.—An entity receiving a grant |
| 21 | under this section shall use grant funds to carry out dem- |
| ~ ~ | |
| 22 | onstration projects, which may include— |
| 22 23 | onstration projects, which may include— "(1) expanding community-based health pro- |

on the prevention of gestational diabetes and obesity
 during pregnancy;

3 "(2) aiding State-based diabetes prevention and
4 control programs to collect, analyze, disseminate,
5 and report surveillance data on women with, and at
6 risk for, gestational diabetes and obesity during
7 pregnancy;

8 "(3) building capacity with State-based part9 ners to implement programs and interventions based
10 on surveillance data; and

11 "(4) training and encouraging health care providers to promote risk assessment, quality care, and self-management for gestational diabetes and obesity during pregnancy and its complications in the practice settings of the health care providers.

16 "(d) Reports.—

17 "(1) CDC REPORT.—Not later than 2 years 18 after the date of enactment of the Gestational Dia-19 betes Act of 2006, the Director of the Centers for 20 Disease Control and Prevention shall prepare and 21 submit a report to the Secretary of Health and 22 Human Services concerning the results of the stud-23 ies conducted through the grants awarded under this 24 section.

"(2) SECRETARY REPORT.—Not later than 90
 days after receiving the report described in para graph (1), the Secretary shall prepare and submit a
 report to Congress concerning the results and find ings of the report.

6 "(e) DEFINITION OF ELIGIBLE ENTITY.—In this sec7 tion, the term 'eligible entity' means a nonprofit organiza8 tion (such as an academic center or community health cen9 ter) or a State health agency.

10 "(f) AUTHORIZATION OF APPROPRIATIONS.—There 11 are authorized to be appropriated to carry out this section 12 \$5,000,000 for fiscal year 2007 and such sums as may 13 be necessary for each of the fiscal years 2008 through 14 2011.

15 "SEC. 2903. RESEARCH EXPANSION OF GESTATIONAL DIA-16 BETES AND OBESITY DURING PREGNANCY.

17 "(a) IN GENERAL.—The Director of the Centers for Disease Control and Prevention and the Director of the 18 19 National Institute of Child Health and Human Development, in collaboration with the National Institute of Dia-20 21 betes and Digestive and Kidney Diseases, shall conduct 22 and support basic, clinical, and public health research re-23 garding gestational diabetes and obesity during preg-24 nancy. Such research shall include—

| 1 | ((1) investigating therapies, interventions, and |
|----|---|
| 2 | agents to detect, treat, and slow the incidence of, |
| 3 | gestational diabetes and obesity during pregnancy; |
| 4 | ((2) developing and testing novel approaches to |
| 5 | the design and analysis of clinical trials; |
| 6 | "(3) facilitating the enrollment of patients for |
| 7 | clinical trials, including patients from diverse popu- |
| 8 | lations and populations who suffer disproportionately |
| 9 | from these conditions; |
| 10 | "(4) developing improved diagnostics and |
| 11 | means of patient assessment for gestational diabetes |
| 12 | and obesity during pregnancy; and |
| 13 | ((5) conducting public health research to fur- |
| 14 | ther knowledge on epidemiologic, socioenvironmental, |
| 15 | behavioral, translation, and biomedical factors that |
| 16 | influence gestational diabetes and obesity during |
| 17 | pregnancy. |
| 18 | "(b) Authorization of Appropriations.—There |
| 19 | are authorized to be appropriated to carry out this section |
| 20 | \$8,000,000 for fiscal year 2007 and such sums as may |
| 21 | be necessary for each of the fiscal years 2008 through |
| 22 | 2011. |
| 23 | "SEC. 2904. SCREENING FOR GESTATIONAL DIABETES. |
| 24 | "The Director of the Centers for Disease Control and |
| 25 | Prevention shall encourage screening for gestational dia- |
| | |

betes within the State-based diabetes prevention and con trol programs assisted by the Centers for Disease Control
 and Prevention, for the purpose of reducing the incidence
 of gestational diabetes and its related complications.".